These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
240 related items for PubMed ID: 25677578
1. Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases. Santos B, Portugal R, Nogueira C, Loureiro M. Transfusion; 2015 Jun; 55(6 Pt 2):1394-8. PubMed ID: 25677578 [Abstract] [Full Text] [Related]
3. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582 [Abstract] [Full Text] [Related]
4. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Win N, New H, Lee E, de la Fuente J. Transfusion; 2008 Jun; 48(6):1231-8. PubMed ID: 18373500 [Abstract] [Full Text] [Related]
5. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Gupta S, Fenves A, Nance ST, Sykes DB, Dzik WS. Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194 [Abstract] [Full Text] [Related]
6. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310 [Abstract] [Full Text] [Related]
7. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with beta-thalassemia: challenges in treatment. Hannema SE, Brand A, van Meurs A, Smiers FJ. Transfusion; 2010 Feb; 50(2):429-32. PubMed ID: 19788508 [Abstract] [Full Text] [Related]
8. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW. Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787 [Abstract] [Full Text] [Related]
9. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Balbuena-Merle R, Hendrickson JE. Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806 [Abstract] [Full Text] [Related]
10. Hyperhemolysis syndrome in anemia of chronic disease. Darabi K, Dzik S. Transfusion; 2005 Dec; 45(12):1930-3. PubMed ID: 16371046 [Abstract] [Full Text] [Related]
11. Prevention of potential delayed hemolytic transfusion reaction in two sickle cell patients using intravenous immunoglobulins and steroids before and after red blood cell exchange with antigen positive units and review literature. Shold J, Dasgupta A, Ye Z. Transfus Apher Sci; 2024 Jun; 63(3):103920. PubMed ID: 38570214 [Abstract] [Full Text] [Related]
12. Utility of hemoglobin electrophoresis to distinguish between severe delayed hemolytic transfusion reaction versus hyperhemolysis syndrome. Lukin R, Law JY, Lokhandwala PM. Transfus Apher Sci; 2024 Jun; 63(3):103919. PubMed ID: 38582651 [Abstract] [Full Text] [Related]
13. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab. Lee LE, Beeler BW, Graham BC, Cap AP, Win N, Chen F. Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065 [Abstract] [Full Text] [Related]
14. A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19. Green A, Jones H, Nero A, Ibrahim IF, Sarode R, Scheid LM, Webb CB, Adkins BD, Yates SG. Transfus Apher Sci; 2023 Aug; 62(4):103712. PubMed ID: 37149492 [Abstract] [Full Text] [Related]
15. Transfusion of multiple units of Js(b+) red blood cells in the presence of anti-Jsb in a patient with sickle beta-thalassemia disease and a review of the literature. Yuan S, Ewing NP, Bailey D, Salvador M, Wang S. Immunohematology; 2007 Aug; 23(2):75-80. PubMed ID: 18004938 [Abstract] [Full Text] [Related]
16. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Vlachaki E, Gavriilaki E, Kafantari K, Adamidou D, Tsitsikas D, Chasapopoulou E, Anagnostopoulos A, Tsapas A. Hemoglobin; 2018 Aug; 42(5-6):339-341. PubMed ID: 30626228 [Abstract] [Full Text] [Related]
17. Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease. Reyes MA, Illoh OC. Immunohematology; 2008 Aug; 24(2):45-51. PubMed ID: 19852130 [Abstract] [Full Text] [Related]
18. Severe neurologic complication after delayed hemolytic transfusion reaction in 2 children with sickle cell anemia: significant diagnosis and therapeutic challenges. Elenga N, Mialou V, Kebaïli K, Galambrun C, Bertrand Y, Pondarre C. J Pediatr Hematol Oncol; 2008 Dec; 30(12):928-30. PubMed ID: 19131783 [Abstract] [Full Text] [Related]
19. Delayed hemolytic transfusion reactions in sickle cell anemia. Rao KR, Patel AR. South Med J; 1989 Aug; 82(8):1034-6. PubMed ID: 2762885 [Abstract] [Full Text] [Related]
20. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Win N, Sinha S, Lee E, Mills W. Transfus Med Rev; 2010 Jan; 24(1):64-7. PubMed ID: 19962576 [Abstract] [Full Text] [Related] Page: [Next] [New Search]